Crospon, which recently announced the finalization of 2,3 million euro in seed financing, will manufacture the skin patch and manage all marketing, sales and support of the technology. The patch delivers medication intradermally - just below the surface of the skin - and enables precise control of dosage timing, access to dosage history, patient activation mechanisms and inherent safety protocols for preventing adverse drug interactions.
Transdermal patches - which rely on absorption through the skin - for nicotine delivery have become a mainstay for smoking cessation programmes; however, they have not been a widely effective delivery mechanism for many drugs because the skin acts as a natural barrier.
The HP-developed skin patch uses microneedles that barely penetrate the skin; this radically reduces discomfort compared to traditional hypodermic needles and enables the technique to be used with a much wider variety of drugs and biopharmaceuticals. The microneedles allow medication to quickly enter the bloodstream, resulting in the potential delivery of lower and more precise dosages.
HP initially developed the drug delivery technology as a way to repurpose its inkjet technology for use in new markets. The technology in the skin patch is similar to that employed in HP's patented process for its inkjet cartridges.
"This industry-first skin patch invented by HP allows Crospon to offer a superior drug delivery platform for doctors and patients", stated John O'Dea, chief executive officer, Crospon. "We look forward to working with our pharmaceutical customers to bring this breakthrough solution to the market."
The agreement between HP and Crospon resulted in part from HP's relationship with Enterprise Ireland, an Irish government agency tasked with supporting and growing indigenous business in Ireland. Through Enterprise Ireland, companies can license the intellectual property of HP and access the company's business and technology mentoring.
"We encourage companies like Crospon to apply HP's intellectual property in innovative ways to help more people benefit from these important technologies", stated Joe Beyers, vice president, Intellectual Property Licensing, HP. "By licensing core intellectual property in thermal inkjet technology for use in a drug delivery product, HP breathes new life into its mature technology while capitalizing on the booming health care and life sciences market."
HP encourages other organisations worldwide to leverage its vast research and development network and portfolio of nearly 30.000 patents to bring new technologies to market through intellectual property licensing agreements. These agreements also enable HP to generate a return on its R&D investment through licensing fees and royalties.
Crospon, formed in 2006, is a medical device company focused on the monitoring and treatment of diabetes and gastro-esophageal reflux disorder (GERD). Crospon recently announced the closure of a 2,3 million euro seed round of financing, which included investment by Enterprise Ireland and The Western Development Commission. Company founder and Chief Executive Officer John O'Dea, previously co-founded Caradyne, a Galway, Ireland-based respiratory products company that was acquired by Respironics Inc. in 2004.
HP focuses on simplifying technology experiences for all of its customers - from individual consumers to the largest businesses. With a portfolio that spans printing, personal computing, software, services and IT infrastructure, HP is among the world's largest IT companies, with revenue totaling $100,5 billion for the four fiscal quarters ended July 31, 2007. More health-related HP news is available in the VMW May 2007 article HP helps University of Utah Health Care improve patient care and lower costs through IT consolidation.